Shares of Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) fell 1.8% on Tuesday . The stock traded as low as $9.40 and last traded at $9.53, with a volume of 62,259 shares. The stock had previously closed at $9.70.

Several brokerages recently weighed in on AQXP. Canaccord Genuity reissued a “buy” rating and issued a $22.00 price objective on shares of Aquinox Pharmaceuticals in a research note on Wednesday, August 17th. Zacks Investment Research cut shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 9th. Needham & Company LLC began coverage on shares of Aquinox Pharmaceuticals in a research note on Thursday, May 12th. They issued a “buy” rating and a $25.00 price objective on the stock. Finally, Jefferies Group boosted their price objective on shares of Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the stock a “hold” rating in a research note on Friday, August 5th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. Aquinox Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $19.86.

The stock’s market cap is $166.10 million. The company’s 50 day moving average price is $8.35 and its 200 day moving average price is $8.37.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($0.63) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by $0.22. Equities analysts expect that Aquinox Pharmaceuticals Inc. will post ($2.08) EPS for the current fiscal year.

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.